• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Hepatic oncology. >Hepatocellular carcinoma and immune therapy, from a clinical perspective; where are we?
【24h】

Hepatocellular carcinoma and immune therapy, from a clinical perspective; where are we?

机译：从临床的角度来看肝细胞癌和免疫疗法; 我们在哪里？

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The incidence of hepatocellular carcinoma (HCC) has been reported to continue to increase in the past decades [l], however we and other groups have found that this might be changing in the USA [2,3]. In our study - based on SEER data - there seemed to be a plateau in incidence rate around 2007, and that the rate of diagnosis in patients with smaller tumors (<5 cm) surpassed larger tumors around 2005. Despite these positive findings, less than 25% of patients received potentially curative treatment with liver transplantation, resection or ablation. In patients who are not candidates for curative treatments, options are limited to transcath-eter arterial chemoembolization (TACE) for intermediate stage disease and, in the advanced disease setting, systemic therapy with sorafenib, the only US FDA-approved drug treatment [4,5]. Recently, a Phase III trial reported that regorafenib in the second-line setting improved overall survival by 2.8 months (10.6 vs 7.8 months) when compared with placebo (HR: 0.62; p < 0.02) [6].
机译：据报道，肝细胞癌（HCC）的发病率在过去的几十年中继续增加[L]，但我们和其他团体发现这可能在美国变化[2,3]。在我们的研究 - 基于SEER数据 - 2007年左右似乎是一个高原，肿瘤患者患者诊断率超过2005年肿瘤较大。尽管这些阳性发现，小于25％的患者接受肝移植，切除或消融的潜在疗效治疗。在患有治疗方法的候选人的患者中，期权仅限于中间阶段病的转基因 - ε动脉化疗（TACE），并且在先进的疾病环境中，Sorafenib的全身治疗，唯一的美国FDA批准的药物治疗[4， 5]。最近，一期审判报道，与安慰剂（HR：0.62; P <0.02）相比，二线设定中的再生赛在二线设定中的总生存率提高了2.8个月（10.6 vs 7.8个月）[6]。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号